Towards an improved investment approach for an effective response to HIV/AIDS

The Lancet

Volumn 377, Issue 9782, 2011, Pages 2031-2041

  Schwartländer, Bernhard ^a   Stover, John ^b   Hallett, Timothy ^c   Atun, Rifat ^d,e   Avila, Carlos ^a   Gouws, Eleanor ^a   Bartos, Michael ^a   Ghys, Peter D ^a   Opuni, Marjorie ^a   Barr, David ^f   Alsallaq, Ramzi ^g   Bollinger, Lori ^b   De Freitas, Marcelo ^h   Garnett, Geoffrey ^c   Holmes, Charles ⁱ   Legins, Ken ^k   Pillay, Yogan ^l   Stanciole, Anderson Eduardo ^m   McClure, Craig ^a   Hirnschall, Gottfried ^a   Laga, Marie ⁿ   Padian, Nancy ^i,j   more..

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b AVENIR HEALTH   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e TUBERCULOSIS AND MALARIA   (Switzerland)

^f International Treatment Preparedness Coalition   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h Brazilian AIDS Program   (Brazil)

ⁱ US President's Emergency Plan for AIDS Relief   (United States)

^j BILL AND MELINDA GATES FOUNDATION   (United States)

^k UNICEF   (United States)

^l Strategic Health Programmes   (South Africa)

^m WORLD BANK   (United States)

ⁿ INSTITUTE OF TROPICAL MEDICINE   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL THERAPY; CONCEPTUAL FRAMEWORK; COST EFFECTIVENESS ANALYSIS; FINANCIAL MANAGEMENT; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; VIRUS TRANSMISSION;

EID: 79958765666     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60702-2     Document Type: Note

References (88)

1. UNAIDS. AIDS 2011: progress, ownership and shared accountability. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS, 2011.
2. UNICEF. Children and AIDS: fifth stocktaking report, 2010. New York, NY, USA: UNICEF, 2010.
3. UNAIDS. Report on the global AIDS epidemic. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS, 2010.
4. United Nations. Report of the Secretary-General: uniting for universal access: towards zero new HIV infections, zero discrimination and zero AIDS-related deaths. http://www.unaids.org/en/media/unaids/contentassets/ documents/document/2011/20110331-SG-report-en.pdf (accessed May 8, 2011).
5. Schwartländer B, Stover J, Walker N, et al. AIDS. Resource needs for HIV/AIDS. Science 2001; 292: 2434-36.
6. UNAIDS. What countries need. Investments needed for 2010 targets. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS, 2009.
7. Merson MH, O'Malley J, Serwadda D, Apisuk C. The history and challenge of HIV prevention. Lancet 2008; 372: 475-88.
8. Samb B, Evans T, Dybul M, et al. An assessment of interactions between global health initiatives and country health systems. Lancet 2009; 373: 2137-69.
9. UNAIDS. Report on the global AIDS epidemic 2008. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS, 2008.
10. Hester V, McGreevey B, Hecht R, Avila C, Gaillard E. Draft working paper: assessing costing and prioritization in national AIDS strategic plans. Results for development institute/AIDS 2031. http://www.resultsfordevelopment.org/sites/ resultsfordevelopment.org/files/resources/Assessing%20Costing%20and%20 Prioritization%20in%20National%20AIDS%20Strategic%20Plans-0.pdf (accessed May 8, 2011).
11. UNAIDS. UNAIDS 2011-2015 strategy: getting to zero. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS, 2011.
12. The Global Fund to Fight AIDS, Tuberculosis and Malaria. The Global Fund 2010. Innovation and impact. http://www. theglobalfund.org/documents/ replenishment/2010/Global-Fund-2010-Innovation-and-Impact-en.pdf (accessed May 8, 2011).
13. The Global Fund to Fight AIDS, Tuberculosis and Malaria. Health systems funding platform pilot. Final decision points for the 22nd board meeting. December, 2010. http://www.theglobalfund.org/ documents/board/22/BM22- DecisionPoints-Report-en.pdf (accessed May 8, 2011).
14. The Global Fund to Fight AIDS, Tuberculosis and Malaria. National strategy aplications first learning wave. Final decision points for the 18th board meeting. November, 2008. http://www.theglobalfund. org/documents/board/18/ GF-BM18-DecisionPoints-en.pdf (accessed May 8, 2011).
15. PEPFAR. PEPFAR: making smart investments to increase impact and efficiency and save more lives. February, 2011. http://www.pepfar.gov/smart/ index.htm (accessed May 8, 2011).
16. aids2031 Costs and Financing Working Group. Costs and choices: financing the long-term fight against AIDS. http://www. resultsfordevelopment.org/sites/ resultsfordevelopment.org/files/ resources/aids2031%20Cost%20&%20Choices.pdf (accessed May 8, 2011).
17. Reza-Paul S, Beattie T, Syed HU, et al. Declines in risk behaviour and sexually transmitted infection prevalence following a community-led HIV preventive intervention among female sex workers in Mysore, India. AIDS 2008; 22 (suppl 5): S91-100.
18. Strathdee SA, Hallett TB, Bobrova N, et al. HIV and risk environment for injecting drug users: the past, present, and future. Lancet 2010; 376: 268-84.
19. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375: 2092-98.
20. Sidibe M, Tanaka S, Buse K. People, passion & politics: looking back and moving forward in the governance of the AIDS response. Glob Health Gov 2010; 4: 1-17.
21. Atun R, de Jongh T, Secci F, Ohiri K, Adeyi O. Integration of targeted health interventions into health systems: a conceptual framework for analysis. Health Policy Plan 2010; 25: 104-11.
22. Victora CG, Habicht JP, Bryce J. Evidence-based public health: moving beyond randomized trials. Am J Public Health 2004; 94: 400-05. (Pubitemid 38269492)
23. Padian NS, McCoy SI, Balkus JE, Wasserheit JN. Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS 2010; 24: 621-35.
24. Padian NS, McCoy SI, Abdool Karim S, et al. HIV prevention transformed: the new prevention research agenda. Lancet (in press).
25. Bollinger LA. How can we calculate the "E" in "CEA"? AIDS 2008; 22 (suppl 1): S51-57.
26. Mofenson LM. Prevention in neglected subpopulations: prevention of mother-to-child transmission of HIV infection. Clin Infect Dis 2010; 50 (suppl 3): S130-48.
27. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial. PLoS Med 2005; 2: e298.
28. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369: 643-56. (Pubitemid 46281312)
29. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369: 657-66.
30. Commission on AIDS in Asia. Redefining AIDS in Asia: crafting an effective response. Report of the Commission on AIDS in Asia. New Delhi, India: Oxford University Press, 2008.
31. Kenya National AIDS Control Programme, UNAIDS, The World Bank. Kenya HIV prevention response and modes of transmission analysis. Nairobi, Kenya: National AIDS Control Programme, 2009.
32. UNAIDS, The World Bank. New HIV infections by mode of transmission in West Africa: a multi-country analysis. Dakar, Senegal: UNAIDS Regional Support Team for West and Central Africa, 2010.
33. European Monitoring Centre for Drugs and Drug Addiction. Harm reduction: evidence, impacts and challenges. In: Rhodes T, Hedrich D, eds. EMCDDA monographs. Luxembourg: Publications Office of the European Union, 2010.
34. WHO, United Nations Office on Drugs and Crime. WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users. Geneva, Switzerland: WHO, UNODC, Joint United Nations Programme on HIV/AIDS, 2009.
35. Long EF, Brandeau ML, Galvin CM, et al. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. AIDS 2006; 20: 2207-15. (Pubitemid 44684712)
36. Hallett TB, Aberle-Grasse J, Bello G, et al. Declines in HIV prevalence can be associated with changing sexual behaviour in Uganda, urban Kenya, Zimbabwe, and urban Haiti. Sex Transm Infect 2006; 82 (suppl 1): 1-8.
37. DiClemente RJ, Salazar LF, Crosby RA. A review of STD/HIV preventive interventions for adolescents: sustaining effects using an ecological approach. J Pediatr Psychol 2007; 32: 888-906. (Pubitemid 350194871)
38. Gregson S, Garnett GP, Nyamukapa CA, et al. HIV decline associated with behavior change in eastern Zimbabwe. Science 2006; 311: 664-66. (Pubitemid 43191311)
39. Halperin DT, Mugurungi O, Hallett TB, et al. A surprising prevention success: why did the HIV epidemic decline in Zimbabwe? PLoS Med 2011; 8: e1000414.
40. The International Group on Analysis of Trends in HIV Prevalence and Behaviours in Young People in Countries most Affected by HIV. Trends in HIV prevalence and sexual behaviour among young people aged 15-24 years in countries most affected by HIV. Sex Transm Infect 2010; 86 (Suppl 2): ii72-83.
41. Hayes R, Kapiga S, Padian N, McCormack S, Wasserheit J. HIV prevention research: taking stock and the way forward. AIDS 2010; 24 (Suppl 4): S81-92.
42. Scalway T. Presenting the evidence for social and behavoural communication. South Africa: Johns Hopkins Health and Education in South Africa, 2010.
43. UNAIDS. Proceedings of the think tank on evaluation methods for HIV prevention. Wilton Park, UK, Sept 1-4, 2009. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS, 2009.
44. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2008; 10: 3879-84. (Pubitemid 351723493)
45. Marconi VC, Grandits GA, Weintrob AC, et al. Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study. AIDS Res Ther 2010; 7: 14.
46. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2010; 10: 155-66.
47. Williams BG, Dye C. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science 2003; 301: 1535-37. (Pubitemid 37128545)
48. Brinkhof MW, Egger M, Boulle A, et al. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis 2007; 45: 1518-21. (Pubitemid 351411886)
49. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20: 1605-12. (Pubitemid 44162402)
50. Middelkoop K, Bekker LG, Myer L, et al. Antiretroviral therapy and TB notification rates in a high HIV prevalence South African community. J Acquir Immune Defic Syndr 2011; 56: 263-69.
51. Sabapathy K, Pujades-Rodriguez M, for the AIDS Working Group of Médecins Sans Frontières. Incidence of tuberculosis in HIV-infected patients before and after starting antiretroviral therapy in 8 sub-Saharan African HIV programs. J Acquir Immune Defic Syndr 2011; published online March 17. DOI:10.1097/QAI.0b013e318218a713.
52. Van Rie A, Westreich D, Sanne I. Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. J Acquir Immune Defic Syndr 2011; 56: 349-55.
53. Williams BG, Granich R, De Cock KM, Glaziou P, Sharma A, Dye C. Antiretroviral therapy for tuberculosis control in nine African countries. Proc Natl Acad Sci USA 2010; 107: 19485-89.
54. Reynolds SJ, Makumbi F, Nakigozi G, et al. HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS 2011; 25: 473-77.
55. Temin M. HIV-sensitive social protection: what does the evidence say? http://regionalcentrebangkok.undp.or.th/practices/HIVAIDS/ documents/ StateofEvidence-MiriamTemin-UNICEF-2010.pdf (accessed May 8, 2011).
56. Stover J, Forsythe S. Financial resources required to achieve national goals for HIV prevention, treatment, care and support. Glastonbury, CT, USA: Futures Institute, 2010.
57. Marseille E, Dandona L, Marshall N, et al. HIV prevention costs and program scale: data from the PANCEA project in five low and middle-income countries. BMC Health Serv Res 2007; 7: 108.
58. Menzies NA, Berruti AA, Berzon R, et al. The cost of providing comprehensive HIV treatment in PEPFAR-supported programs. AIDS 2011; published online March 15. DOI:10.1097/QAD.0b013e3283463eec.
59. Rosen S. PEPFAR-supported evaluations of the cost and cost-effectiveness of HIV/AIDS treatment delivery in Africa: Boston University's experience. Boston University, MA, USA: Center for Global Health and Development, 2011.
60. Jouquet G, Bemelmans M, Massaquoi M, et al. Economic evaluation and financing HIV/AIDS: Cost analysis of an ARV care programme reaching universal access in Thyolo, Malawi. 5th International AIDS Society Conference; Cape Town, South Africa; July 19-22, 2009.
61. UNAIDS. Treatment 2.0. http://data.unaids.org/pub/ Outlook/2010/20100713- outlook-treatment2-0-en.pdf (accessed May 8, 2011).
62. Hirnschall G, Schwartländer B. Treatment 2.0: catalysing the next phase of scale-up. Lancet 2011; published online Feb 25. DOI:10.1016/S0140- 6736(11)60247-X.
63. Low-Beer D, Sempala M. Social capital and effective HIV prevention: community responses. Glob Health Gov 2010; IV: 1-18.
64. Frumence G, Killewo J, Kwesigabo G, Nystrom L, Eriksson M, Emmelin M. Social capital and the decline in HIV transmission - a case study in three villages in the Kagera region of Tanzania. Sahara J 2010; 7: 9-20.
65. Sweat M, Morin S, Celentano D, et al. Community-based intervention to increase HIV testing and case detection in people aged 16-32 years in Tanzania, Zimbabwe, and Thailand (NIMH Project Accept, HPTN 043): a randomised study. Lancet Infect Dis 2011; published online May 4. DOI:10.1016/S1473-3099(11)70060- 3.
66. Kunihira NR, Nuwaha F, Mayanja R, Peterson S. Barriers to use of antiretroviral drugs in Rakai district of Uganda. Afr Health Sci 2010; 10: 120-29.
67. MacNeil J, Pauly B. Needle exchange as a safe haven in an unsafe world. Drug Alcohol Rev 2011; 30: 26-32.
68. Nyamathi AM, Sinha S, Ganguly KK, et al. Challenges experienced by rural women in India living with AIDS and implications for the delivery of HIV/AIDS care. Health Care Women Int 2011; 32: 300-13.
69. Shin S, Munoz M, Zeladita J, et al. How does directly observed therapy work? The mechanisms and impact of a comprehensive directly observed therapy intervention of highly active antiretroviral therapy in Peru. Health Soc Care Community 2010; 19: 261-71.
70. Narayanan S, Vicknasingam B, Robson NM. The transition to harm reduction: Understanding the role of non-governmental organisations in Malaysia. Int J Drug Policy 2011; published online Feb 5. DOI:10.1016/j.drugpo.2011.01.002.
71. Oosterhoff P, Anh NT, Yen PN, Wright P, Hardon A. HIV-positive mothers in Viet Nam: using their status to build support groups and access essential services. Reprod Health Matters 2008; 16: 162-70.
72. Kaiser Family Foundation, UNAIDS. Financing the response to AIDS in low-and middle-income countries: International assistance from the G8, European Commission and other donor governments in 2009. http://www.stimson.org/images/ uploads/research-pdfs/2009-Report.pdf (accessed May 8, 2011).
73. WHO. WHO guide to cost-effectiveness analysis. Geneva, Switzerland: World Health Organization, 2003.
74. Atun R, Kazatchkine M. The Global Fund's leadership on harm reduction: 2002-2009. Int J Drug Policy 2010; 21: 103-06.
75. Grown C, Bahadur C, Handbury J, Elson D. The financial requirements of achieving gender equality and women's empowerment. http://siteresources. worldbank.org/INTGENDER/ Resources/ GrownBahadurHandburyElsonFinancialRequirements. pdf (accessed April 12, 2011).
76. UNESCO. Institute for statistics. http://www.uis.unesco.org/ev- en.php?ID=3753-201&ID2=DO-TOPIC (accessed April 12, 2011).
77. WHO. Country health information, 2010. http://www.who.int/nha/ country/en (accessed April 12, 2011).
78. United Nations. Declaration of Commitment on HIV/AIDS. UN General Assembly Special Session on HIV/AIDS. New York, USA: United Nations, 2001.
79. Pronyk PM, Hargreaves JR, Kim JC, et al. Effect of a structural intervention for the prevention of intimate-partner violence and HIV in rural South Africa: a cluster randomised trial. Lancet 2006; 368: 1973-83. (Pubitemid 44821362)
80. Loevinsohn M, Gillespie S. HIV/AIDS, food security and rural livelihoods: understanding and responding (FCND Discussion paper no. 157) Washington, DC, USA: International Food Policy Research Institute, 2003.
81. Atun RA, Gurol-Urganci I, McKee M. Health systems and increased longevity in people with HIV and AIDS. BMJ 2009; 338: b2165.
82. The Global Fund to Fight AIDS, Tuberculosis and Malaria. Third replenishment 2011-13. Financial and health impacts of continued support to the three diseases: long-term estimates. http://www. theglobalfund.org/documents/ replenishment/2010/Financial-and-Health%20Impacts-of-Continued-Support-to-the- Three- Diseases-Long%20Term%20Estimates.pdf (accessed May 8, 2011).
83. Lewin S, Munabi-Babigumira S, Glenton C, et al. Lay health workers in primary and community health care for maternal and child health and the management of infectious diseases. Cochrane Database Syst Rev 2010; 3: CD004015.
84. Callaghan M, Ford N, Schneider H. A systematic review of task-shifting for HIV treatment and care in Africa. Hum Resour Health 2010; 8: 8.
85. Hermann K, Van Damme W, Pariyo GW, et al. Community health workers for ART in sub-Saharan Africa: learning from experience - capitalizing on new opportunities. Hum Resour Health 2009; 7: 31.
86. Philips M, Zachariah R, Venis S. Task shifting for antiretroviral treatment delivery in sub-Saharan Africa: not a panacea. Lancet 2008; 371: 682-84. (Pubitemid 351273400)
87. Schneider H, Hlophe H, van Rensburg D. Community health workers and the response to HIV/AIDS in South Africa: tensions and prospects. Health Policy Plan 2008; 23: 179-87.
88. National Institutes of Allergy and Infectious Diseases and National Institutes of Health. Questions and Answers. The HPTN 052 study: preventing sexual transmission of HIV with anti-HIV drugs. http://www.niaid.nih.gov/news/ QA/Pages/HPTN052qa.aspx (accessed May 15, 2011).